Adults 18 to 70, any sex, with Leukemia or Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression Free Survival/PFS at 1 Year Post UCBT.Primary· 1 year post UCBT
To obtain a preliminary estimate of progression free survival at 1 year post UCBT. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Group
Value
95% CI
Participants With Hematologic Malignancies
84
77 – 92
Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT RecipientsSecondary· up to 13 days from engraftment
Successful primary donor engraftment = neutrophill recovery within the first 45 days after transplant and partial/complete donor chimerism (\>/= 10%)
Haplo-dCBT with early haplo-derived myeloid bridge
Group
Value
95% CI
Participants With Hematologic Malignancies
17
Haplo-dCBT with transient haplo-derived bridge with second neutrophil nadir
Group
Value
95% CI
Participants With Hematologic Malignancies
13
Haplo-dCBT with no bridge
Group
Value
95% CI
Participants With Hematologic Malignancies
13
Remaining dCBT recipient
Group
Value
95% CI
Participants With Hematologic Malignancies
43
Percentage of Participants With Sustained CB-derived Neutrophil EngraftmentSecondary· 100 days
The day 100 cumulative incidence of sustained CB-derived neutrophil engraftment.
Group
Value
95% CI
Participants With Hematologic Malignancies
99
87 – 99
Percentage of Participants With Sustained CB-derived Platelet EngraftmentSecondary· 100 days
The day 100 cumulative incidence of sustained CB-derived platelet engraftment to \>/= 20 x 10\^9/L
Group
Value
95% CI
Participants With Hematologic Malignancies
93
85 – 97
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 3 years.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The traditional way of doing a donor transplant is to give high doses of chemotherapy and radiation before giving the stem cells. However, high doses of chemotherapy and radiation can have serious side-effects. The doctors think that the transplant will be safer and more likely to be successful with reduced doses of chemotherapy and radiation. The purpose of this study is to find out how good a combination of chemotherapy and radiation at reduced doses followed by a cord blood transplant are at treating cancer.
The stem cells chosen for the transplant are from umbilical cord blood. Umbilical cord blood is collected from healthy newborn babies and frozen. One cord blood collection is called a "cord blood unit." On transplant day, the cord blood will be given through the catheter just like a blood transfusion. Transplants done this way have been successful. However, this type of transplant is fairly new. Therefore, it is important to study it so the doctors can better understand how it works.
Most blood or bone marrow transplants using donor stem cells are done as part of a study. When patients are on a study we test new ways of treating them which we think may be better than the old ways. We collect information about the result of this treatment so we can understand how well the treatment works. This is so we can learn better ways to treat our patients.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
· NA
· recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
· Phase 2
· recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
· recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia:
· Phase 1, PHASE2
· recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery
· Phase 3
· recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
· Phase 2
· recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term
· Phase 2
· recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 8 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00739141.